Literature DB >> 3919231

Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study.

T T Jung, N T Berlinger, S K Juhn.   

Abstract

It has already been demonstrated in human and animal systems that PGE2 is a suppressor signal for many immune functions. These include T-lymphocyte blastogenesis, natural killer cell activity, and cytolytic T-lymphocyte activity. These functions are important for destruction of tumor cells. Conceivably, suppression of these functions by excessive PGE2 restricts tumor cell kill, and reversal of suppression by an inhibitor of prostaglandin synthesis such as indomethacin could increase tumor cell kill. The purpose of this study was to determine the kind of prostaglandins (PGs) produced by tissues with squamous cell carcinoma of head and neck and to measure the concentrations of PGE2, 6-keto-PGF1 alpha, and thromboxane (Tx) B2 in the tumor tissue and in the corresponding control tissue. Tumor and normal control tissues at the margin of the resection were obtained from surgical specimens. The production of PGs was determined by incubation of tissue homogenates with 14C-arachidonic acid, by thin layer chromatography, autoradiography, and scintillation counting. Concentrations of PGs were measured by radioimmunoassay. Tumor tissues produced PGD2, E2, TxB2, F2 alpha, and 6-keto-F1 alpha, and 15-, 12-, and 5-monohydroxyeicosatetraenoic acid (HETE). Concentrations of PGE2 were four times higher in the tumor tissues compared to those in control tissues. There was no difference between the levels of TxB2 and 6-keto-PGF1 alpha in the tumor tissues and those in control tissues. The results of this study will serve as basic information necessary for the potential use of inhibitors of PG-synthesis in the treatment of head and neck carcinoma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3919231     DOI: 10.1288/00005537-198503000-00014

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  14 in total

1.  Interaction between head and neck squamous cell carcinoma cells and fibroblasts in the biosynthesis of PGE2.

Authors:  Sonia Alcolea; Rosa Antón; Mercedes Camacho; Marta Soler; Arantzazu Alfranca; Francesc-Xavier Avilés-Jurado; Juan-Miguel Redondo; Miquel Quer; Xavier León; Luis Vila
Journal:  J Lipid Res       Date:  2012-02-04       Impact factor: 5.922

2.  Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers.

Authors:  Neil D Gross; Jay O Boyle; Jason D Morrow; Myles K Williams; Chaya S Moskowitz; Kotha Subbaramaiah; Andrew J Dannenberg; Anna J Duffield-Lillico
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

3.  Prognostic significance of plasma prostaglandin E concentration in patients with head and neck cancer.

Authors:  I Klapan; V Katić; F Culo; V Cuk
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

4.  Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.

Authors:  C K Martin; W P Dirksen; M M Carlton; L G Lanigan; S P Pillai; J L Werbeck; J K Simmons; B E Hildreth; C A London; R E Toribio; T J Rosol
Journal:  Vet Comp Oncol       Date:  2013-05-08       Impact factor: 2.613

5.  Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab.

Authors:  Neil E Bhola; Sufi M Thomas; Maria Freilino; Sonali Joyce; Anirban Sahu; Jessica Maxwell; Athanassios Argiris; Raja Seethala; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2011-06-08       Impact factor: 12.531

6.  Cannabis smoke can be a major risk factor for early-age laryngeal cancer--a molecular signaling-based approach.

Authors:  Sayantan Bhattacharyya; Syamsundar Mandal; Samir Banerjee; Gautam Kumar Mandal; Anup Kumar Bhowmick; Nabendu Murmu
Journal:  Tumour Biol       Date:  2015-03-04

7.  Aspirin use and head and neck cancer survival: an observational study of 11,623 person-years follow-up.

Authors:  Shin-Ae Kim; Jong-Lyel Roh; Sung-Bae Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Int J Clin Oncol       Date:  2017-07-19       Impact factor: 3.402

8.  Decreased risk of squamous cell carcinoma of the head and neck in users of nonsteroidal anti-inflammatory drugs.

Authors:  Neda Ahmadi; Radoslav Goldman; Françoise Seillier-Moiseiwitsch; Anne-Michelle Noone; Ourania Kosti; Bruce J Davidson
Journal:  Int J Otolaryngol       Date:  2010-06-03

9.  Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients.

Authors:  Vikram D Kekatpure; Jay O Boyle; Xi Kathy Zhou; Anna J Duffield-Lillico; Neil D Gross; Nancy Y Lee; Kotha Subbaramaiah; Jason D Morrow; Ginger Milne; Scott M Lippman; Andrew J Dannenberg
Journal:  Cancer Prev Res (Phila)       Date:  2009-10-20

10.  Production of prostaglandin E by squamous carcinoma of the head and neck and adenocarcinoma of gastrointestinal tissue.

Authors:  F Culo; I Klapan; V Katić; T Kolak; B Bakula
Journal:  Med Oncol Tumor Pharmacother       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.